ProfileGDS5678 / 1429499_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 84% 79% 81% 81% 80% 80% 75% 76% 80% 81% 79% 78% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4827879
GSM967853U87-EV human glioblastoma xenograft - Control 26.2408684
GSM967854U87-EV human glioblastoma xenograft - Control 35.5769879
GSM967855U87-EV human glioblastoma xenograft - Control 45.9331781
GSM967856U87-EV human glioblastoma xenograft - Control 55.8697381
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4482280
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.51680
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9425275
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1061176
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6878280
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8335681
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.580679
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2960178
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6846280